Premium
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy
Author(s) -
Salati Massimiliano,
Tarantino Vittoria,
Maiorana Antonino,
Bettelli Stefania,
Luminari Stefano
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2315
Subject(s) - lenalidomide , medicine , oncology , complete remission , multiple myeloma , chemotherapy
Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B‐cell lymphoma and presents as leptomeningeal dissemination in two‐thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6‐positive double‐hit diffuse large B‐cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single‐agent lenalidomide following salvage chemotherapy. Copyright © 2016 John Wiley & Sons, Ltd.